After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

A readout from the company’s SUMMIT trial put its small molecule bezuclastinib on a collision course with rival Blueprint’s ...

The partnership will give Chugai access to Gero’s artificial intelligence technology to discover novel targets in ...

Slashing adverse drug reactions through pharmacogenetics and advanced AI could help rehabilitate the pharmaceutical ...

Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...